Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in Australia
TOKYO and CAMBRIDGE, Mass., Oct 17, 2024 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to register the humanized anti-solubleaggregated amyloid-beta (Aβ) monoclonal antibody lecanemab for the treatment of patients with mild […]